Imaging and therapeutic targeting of the tumor immune microenvironment with biologics

Adv Drug Deliv Rev. 2022 May:184:114239. doi: 10.1016/j.addr.2022.114239. Epub 2022 Mar 26.

Abstract

The important role of tumor microenvironmental elements in determining tumor progression and metastasis has been firmly established. In particular, the presence and activity profile of tumor-infiltrating immune cells may be associated with the outcome of the disease and may predict responsiveness to (immuno)therapy. Indeed, while some immune cell types, such as macrophages, support cancer cell outgrowth and mediate therapy resistance, the presence of activated CD8+ T cells is usually indicative of a better prognosis. It is therefore of the utmost interest to obtain a full picture of the immune infiltrate in tumors, either as a prognostic test, as a way to stratify patients to maximize therapeutic success, or as therapy follow-up. Hence, the non-invasive imaging of these cells is highly warranted, with biologics being prime candidates to achieve this goal.

Keywords: Antibodies; CAR T cells; Immunotherapy; Molecular imaging; Myeloid cells; Nanobodies; T cells; T-cell adoptive therapy; Tumor-associated macrophages.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biological Products* / metabolism
  • Biological Products* / therapeutic use
  • CD8-Positive T-Lymphocytes / metabolism
  • Humans
  • Immunotherapy / methods
  • Neoplasms* / drug therapy
  • Neoplasms* / metabolism
  • Prognosis
  • Tumor Microenvironment

Substances

  • Biological Products